Podcasts about Keynote

Hi, I'm the Profit Answer Man Rocky Lalvani! I help small business owners simplify their financial reports so that they can make more informed business decisions with fewer hassles. We utilize the Profit First system created by Mike Michalowicz Effortless Cashflow Course: http://bit.do/effortlesscashflowcourse Schedule your free, no-obligation intro call: https://bookme.name/rockyl/lite/intro-appointment-15-minutes More about making profitability simple: http://profitcomesfirst.com/ Bio The Sales CEO has over 25 years of experience training individuals and teams on high performance sales processes. The Sales CEO is a boutique coaching firm specializing in sales development with a focus on ADHD. Using his ADHD superpower Corey  has developed systems and processes that allow Business owners to maximize employee experience and revenue.   Corey uses a proprietary system to guide businesses to higher sales results, focusing on every aspect of the process. A hands-on approach is used, with feedback provided throughout the entire process, which helps clients to achieve results faster. Our proven results have helped hundreds of professionals across multiple industries achieve improved sales results.     Corey is a Keynote speaker, International Coach and Consultant and hosts the Top Rated podcast “Successful Life Podcast” and he co hosts the only ADHD sales Podcast in the world called “ADHD SALES LEGENDS', with Callye Keen.     Corey is writing a book on ADHD Sales and Entrepreneurship that will be out later this year.   Links: https://coreyberrier.com/ https://www.instagram.com/coreyberrier/ http://www.linkedin.com/in/coreysalescoach https://www.youtube.com/channel/UCrPl4lUyKV7hZxoTksQDsyg Questions: questions@profitanswerman.com Email: rocky@profitcomesfirst.com Profit Answer Man Facebook group: https://www.facebook.com/groups/profitanswerman/ My podcast about living a richer more meaningful life: http://richersoul.com/ First 2 chapters of Profit First: https://sendfox.com/rocky This episode is part of the SMB Podcast Network. Find other great interviews from around the internet just like this one at https://www.SMBPodcastNetwork.com Music provided by Junan from Junan Podcast Any financial advice is for educational purposes only and you should consult with an expert for your specific needs.

He was the guest that changed everything for us, and now we go again! Listen to this exclusive preview of our special collaboration with the podcast 'I AM...with Jonny Wilkinson'. Jake and Damian tease the full episode, which is released on Thursday 7th July!- - - - - -Watch all our episodes on YouTube : https://www.youtube.com/c/HighPerformancePodcast/videosFollow us on Instagram: https://www.instagram.com/highperformance/Follow us on Facebook: https://www.facebook.com/highperformancepodcastJoin our new Telegram: https://t.me/highperformance_circleAnd join our new Telegram for behind-the-scenes access and exclusive competitions: https://t.me/highperformance_circleThis month's HIGH PERFORMANCE CIRCLE newsletter is out! Released at the start of each month, the newsletter will include: a note from Jake, a Boost (short 10 minute piece of video content), Keynote (longer video content) and a ‘Thought from The Professor' (inspiration from Damian!)Just go to https://www.thehighperformancepodcast.com/thecircle See acast.com/privacy for privacy and opt-out information.

In this episode, I share a brief clip from a 19-minute presentation that I was scheduled to give at the Latter-day Saint Educators Conference held at BYU on June 24, 2022. I had bronchitis on that day, so I asked my son Richard to substitute for me. I highly recommend his presentation to you. You will notice in this video that the Keynote slides help a lot. So if you're interested in the full presentation, just click on the link below. That will take you to my YouTube Channel.https://youtube.com/channel/UC8Atnq_XbwzA3bQkKZKz5fwYou will notice that I have begun to publish videos of each podcast in Season 2 on this channel. So if you're interested, feel free to subscribe, and you will receive each video episode presentation as it is published.

AJ Tracey (Ché Woltuhin Grant) is a British singer-songwriter, producer, platinum selling and Brit nominated artist. AJ is known for his campaigns for justice, especially his ongoing support of Grenfell United. He was cited as one of the main reasons young people in his area of West London began voting. In this episode he shares the priceless opportunity his mum gave him by supporting him for a year to pursue music and how important that parental belief was. AJ discusses how confidence needs to come from within, his self-belief is what drives him - not outside sources.Self-understanding and reflection is a crucial part of AJ's career, rather than jumping at every opportunity he says he needs to “understand his own level” and not choose quick success over personal growth. He shares how important it is for him to return to Ladbroke Grove, where he grew up, and tackle poverty and inequality. - - - - - -Watch all our episodes on YouTube : https://www.youtube.com/c/HighPerformancePodcast/videosFollow us on Instagram: https://www.instagram.com/highperformance/Follow us on Facebook: https://www.facebook.com/highperformancepodcastJoin our new Telegram: https://t.me/highperformance_circleAnd join our new Telegram for behind-the-scenes access and exclusive competitions: https://t.me/highperformance_circleThis month's HIGH PERFORMANCE CIRCLE newsletter is out! Released at the start of each month, the newsletter will include: a note from Jake, a Boost (short 10 minute piece of video content), Keynote (longer video content) and a ‘Thought from The Professor' (inspiration from Damian!)Just go to https://www.thehighperformancepodcast.com/thecircle See acast.com/privacy for privacy and opt-out information.

Kara Swisher, a contributing writer to the New York Times Opinion section and podcast host for Sway and Pivot, is described as Silicon Valley's "most powerful tech journalist.” Holly Enneking, Vice President of Marketing at Lev, leads a conversation with Kara about accountability -- both for Big Tech leaders and everyday digital marketers -- as well as being unapologetically yourself.Conversation topics include: The Reckoning in tech, and how leaders can best manage their communication platforms and systemsPreserving online privacy, data ickiness, and how we should be thinking about cyber attacksThe Metaverse, vaporware, Twitter, and Elon MuskRepresentation and innovation in the tech industryKara's thoughts on her career, on respecting audiences, and advice for female journalists

July 1, 2022: A special episode of Keynote this week combines different guests and topics that really illustrate what this channel is all about and what conversations we've been able to have the past 6 months. We've clipped together some of our favorite moments, though it was hard to choose just a few. In Part 1 of our curated playlist, we feature the following guests and topics: 1. Mark Cuban, American billionaire & entrepreneur, Mark Cuban Cost Plus Drug Company - https://youtu.be/uGrhGnB4XoM (How will Mark Cuban Break into the Existing Systems in Healthcare to Make Equity Changes?) 2. John Halamka, President of Mayo Clinic Platform - https://youtu.be/yyBrKCUYOCE (AI and the Future of the EHR in Healthcare) 3. Angela Yochem, EVP Chief Transformation & Digital Officer at Novant Health - https://youtu.be/0MM_sRyNjwc (The Future Of Healthcare Is Empowering The Individual To Manage Their Wellness In A Continuum) 4. Lee Shapiro, Managing Partner at 7wireVentures - https://youtu.be/qSkj5PghCX0 (2022 Fundraising Predictions from Managing Partner of 7WireVentures) 5. Glen Tullman, CEO at Transcarent - https://youtu.be/sOq9T9adsxs (How Transcarent is Challenging the Confusing, Complex, and Costly State of Healthcare) 6. Missy Krasner, Venture Chair at Redesign Health - https://youtu.be/V7om0ZjE-fU (Big Tech's Decentralized Approach To Healthcare Innovation And Its Affect On Partnerships) 7. Rob DeMichiei, Former CFO / Board Director and Strategic Advisor at Health Catalyst- https://youtu.be/mBNPsyOfBGI (Healthcare Providers Reassess Strategy to Compete with 2022 Landscape) 8. Lee Milligan, CIO at Asante - https://youtu.be/u12sN2jK-_I (The First Moments of a Ransomware Attack: That First Phone Call)

Today's episode is from the Brand Minds conference in Bucharest, Romania! This conversation is an well-rounded piece that focuses on attention arbitrage, communication, Web 3 and so much more. There's something in here for EVERYONE to find vvalue in and I know you're going to love it. Enjoy! Let me know what you thought. Check out my new NFT project: veefriends.com Join the VeeFriends Discord: https://discord.gg/veefriends Tweet Me! @garyvee Text Me! 212-931-5731 My Newsletter: garyvee.com/newsletter

Quality over quantity! Today, join Alex (@AlexHormozi) as he shares one of his favorite Keynote speeches about the heart and soul of building a brand and the mistakes that some people aspiring entrepreneurs tend to repeat when starting out on creating content. This is part 2 of the talk. Welcome to The Game Podcast where we talk about how to get more customers, make more profit per customer, and keep them longer, and the many failures and lessons we have learned along the way to $100M in sales. We've got roll-up-your-sleeves kind of hustle with a little bit of cleverness and a lot of heart. Timestamps: 1:25 - There are two frame shifts that have to happen: “Here's What I Did” vs. “Here's What I Should Do” 5:59 - You can become a niche-specific authority rather than being generic  13:46 - You gain more authority by saying “I don't have authority to speak on that.” 18:14 - It's actually more beneficial to “give away your secrets, sell the implementation” in your content. This is how you build a brand 21:51 ​​- Talk about what you really know, your specialty Your individual thing that you have experienced & that no one can challenge your truth Follow Alex Hormozi's Socials: https://www.linkedin.com/in/alexanderhormozi (LinkedIn ) | https://www.instagram.com/hormozi/?hl=en (Instagram) | https://www.facebook.com/alex.hormozi (Facebook) | https://www.youtube.com/c/AlexHormozi (YouTube ) | https://twitter.com/AlexHormozi?s=20&t=J9vPh75tO3ow9xExYLsBDQ (Twitter) | https://www.acquisition.com/ (Acquisition )

Today's motivation is an outline of what it takes to succeed. Audio Source: https://www.youtube.com/watch?v=6uUeYSw4JlY&t=144s More about Brian: Brian's goal is to help you achieve your personal and business goals faster and easier than you ever imagined. Brian Tracy has consulted for more than 1,000 companies and addressed more than 5,000,000 people in 5,000 talks and seminars throughout the US, Canada and 70 other countries worldwide. As a Keynote speaker and seminar leader, he addresses more than 250,000 people each year. Quote of the Day: "Never complain, never explain. Resist the temptation to defend yourself or make excuses.” ― Brian Tracy Leave a review Support via Patreon Check out my Personal Finance/Investing Podcast --- Support this podcast: https://anchor.fm/motiv8/support

You've got big ideas that you know could help people. But it's hard to articulate that insight as an actionable plan for business partners, clients, and investors.  So, how do you move forward? Today, we're sitting down with Tamsen Webster, a TedX speaker and author of the new book Find Your Red Thread: Make Your Big Ideas Irresistible. In her insightful text, Tamsen codifies her method, and helps others find the throughline that connects an idea to the hearts and minds of the audience. Many new authors suffer from the "curse of the expert," unable to put their methodology and processes on the page in a way that's accessable to beginners. For Tamsen, that was the easy part. In fact, she struggled with letting go of the book, unsure that the process she had been successfully using for the previous five years was enough to warrant publishing. As with any good business book, Tamsen has found that hers has drawn multiple new clients — without the usual 2 degrees of separation. Now, people are finding the book and reaching out to her on their own, and that's growing her business exponentially. She's also dipped a toe into licensing her IP, and creating an accreditation program to help other businesses share her Red Thread method with their clients.  Lastly, we discuss the hard part of creating and licensing a properly… protecting it. In order to maintain your trademark, you have to defend it. This can mean awkward conversations about how and where your method can be used. Unfortunately, many people who are interested in thought leadership content are unaware that they are violating copyrights, but there are ways to handle such issues amicably, and to the advantage of both parties. This interview is a great example of a thought leadership book propelling your ideas to scale! Three Key Takeaways: * When writing a thought leadership book, remember to clearly convey what you do best. * Construct your chapter outline by ensuring that instructions before theoretical examples. This way the most useful part comes first. * When writing a thought leadership book, consider creating an accreditation program to give organizations a legitimate way to institute your trademarked ideas.

Today, I couldn't be more excited to introduce you to Carrie Freeman, the Co-CEO of SecondMuse, an impact and innovation company that builds resilient economies, and the 2022 Extraordinary Women Ignite Keynote! Now more than ever before, women are being called to raise up our voices, vision, and visibility. Carrie is leading with empathy and compassion. I couldn't think of a better speaker to uplift the conference and ignite a positive change in the attendees. In this Episode: Carrie shares ways to use technology; for good, collaboration, relationships, and to deepen the human connection The importance of environmental sustainability How to increase relational wealth Different approaches to support other people within our community Why education and equality are essential to raising the impact women can make in the world Ways to increase formalized opportunities for women Tips on how to give yourself permission and grace in the workforce Carrie's insight into being more intentional with decision making Carrie Freeman, the Co-CEO of SecondMuse, an impact and innovation company that builds resilient economies. Since 2012, she has been steering the global company's approach to finding and nurturing innovators dedicated to social and environmental good, and building supportive ecosystems around them. Its mission aligns with Carrie's fundamental belief in the infinite capacity for humans to learn and grow, and the potential for inclusive markets and businesses to massively scale positive change. Under Carrie's leadership, SecondMuse has run programs that define inspiring visions, build lasting businesses and unite people across the globe. Over the last decade, while growing 40% year over year, they've designed and implemented programs on 7 continents with 600+ organizations such as NASA, The World Bank, Pivotal Ventures and Nike. Her organization has prototyped 30,000+ solutions, enabled $325 million of investment to support ventures and generated $10B of social and environmental impact. Carrie's experiences at SecondMuse have strengthened her conviction that deep, sustained collaboration between governments, businesses, and the communities in which they operate, fosters innovation. "We can have all the technology we want in the world, but it is people that actually make the difference." -Carrie Freeman To learn more about Carrie and her work, check out the website for SecondMuse. You can also connect with her via the company's Facebook, Instagram, LinkedIn, or Twitter account. Register for the Extraordinary Women Ignite Conference, where Carrie will join us as our keynote! Let's Meet Carrie Freeman. Carrie Freeman Show Notes 

Continuing the conversation with Kristina Hoyer, John discusses the relationship aspect of her life. The first part of the interview (Episode 107) focused on her journey into the US Navy and her life as a human performance coach. Listen to this episode to learn more: [00:00] - When mindset and wellness go hand in hand [04:36] - Kristina's go-to supplements [08:22] - Kristina's approach to strengthening relationships and how they impact her business [10:53] - The importance of community [13:43] - Harmonizing your personal and professional lives [16:10] - Kristina's non-negotiable habits [18:58] - John's go-to habits [21:35] - How John feels when he is meditating and when he is not [31:00] - Books Kristina is reading [33:00] - Meaning of the word “Meek” [38:23] - Podcast Kristina listens to on a regular basis NOTABLE QUOTES: "You are the epicenter; you're the driver for your personal brand or businesses for the most part. If you are not doing well, your business is not. And one of the main pillars of human health is community."  "You don't know the level of support you can have until you give someone the opportunity to support you. And the feeling that connected, supported, cared for, and loved bolsters every part of your life." "If you are a personal brand, business, or a CEO, the more supported you are the more full you are; the more connected you are, the more heart-centered and heart-driven you can be."  "Most awesome thing about humanity is that we have the capability to become wildly invested in something." "You have to know what it is that you need to do for you. And once you figure those things out, those are the things you need to do." "We have to build in white space … because there has to be room for life to happen." BOOKS MENTIONED: Mary Magdalene Revealed: The First Apostle, Her Feminist Gospel & the Christianity We Haven't Tried Yet by Meggan Watterson (https://tinyurl.com/MaryMagdaleneRevealedBook) Power vs. Force: The Hidden Determinants of Human Behavior by David R. Hawkins (https://tinyurl.com/PowerVsForceBook) PODCAST MENTIONED: The Huberman Lab Podcast (https://tinyurl.com/HubermanLabPdcst) USEFUL RESOURCES: https://www.kristinahoyercollective.com  https://www.instagram.com/kristinahoyercollective/  https://www.facebook.com/Kristina-Hoyer-Collective-112781317226104  https://www.linkedin.com/in/kristinahoyer/  CONNECT WITH JOHN Website - https://thejohnhulen.com  Instagram - https://www.instagram.com/johnhulen  Facebook - https://www.facebook.com/johnhulen  Twitter - https://www.twitter.com/johnhulen  LinkedIn - https://www.linkedin.com/in/johnhulen  YouTube - https://www.youtube.com/channel/UCLX_NchE8lisC4NL2GciIWA  EPISODE CREDITS Intro music provided by Tony Palacios - https://www.instagram.com/tonytonedog/  Outro music provided by Jeff Scheetz - https://jeffscheetz.com/ 

Mobile Tracking, Safari's WebKit, NBA All-World  Base 13-Inch MacBook Pro with M2 chip appears to have significantly slower SSD speeds.  US senators ask FTC to investigate Apple and Google over mobile tracking.  Russia threatens Apple with fines for not storing user data within the country.  U.S. Supreme Court won't hear Apple's bid to revive Qualcomm patent challenges.  How refactoring code in Safari's WebKit resurrected 'zombie' security bug.  Uyghur Forced Labor Prevention Act - enforcement begins.  Apple Watch Series 8 rumored to feature new Low Power Mode.  Apple readies iPhone 14 and HomePod upgrade in flood of new products.  AirPods Max beta confirms higher quality Bluetooth codec.  AirPods Pro 2 case redesign with rumored Find My feature shown off in leak, earbud appearance unchanged.  Pokémon Go makers take on basketball with NBA All-World.  For All Mankind' prop fused an Apple Newton MessagePad 120 and an iPhone 12.  iWork update brings new features to Pages, Numbers, and Keynote with version 12.1. Picks of the Week Alex's Pick: Craiyon Andy's Pick: Tot Rene's Pick: Moment Anamorphic Adapter Hosts: Alex Lindsay, Rene Ritchie, Andy Ihnatko, and Mikah Sargent Download or subscribe to this show at https://twit.tv/shows/macbreak-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: nomadgoods.com/MACBREAK onepeloton.com go.newtek.com/twit-tv

Mobile Tracking, Safari's WebKit, NBA All-World  Base 13-Inch MacBook Pro with M2 chip appears to have significantly slower SSD speeds.  US senators ask FTC to investigate Apple and Google over mobile tracking.  Russia threatens Apple with fines for not storing user data within the country.  U.S. Supreme Court won't hear Apple's bid to revive Qualcomm patent challenges.  How refactoring code in Safari's WebKit resurrected 'zombie' security bug.  Uyghur Forced Labor Prevention Act - enforcement begins.  Apple Watch Series 8 rumored to feature new Low Power Mode.  Apple readies iPhone 14 and HomePod upgrade in flood of new products.  AirPods Max beta confirms higher quality Bluetooth codec.  AirPods Pro 2 case redesign with rumored Find My feature shown off in leak, earbud appearance unchanged.  Pokémon Go makers take on basketball with NBA All-World.  For All Mankind' prop fused an Apple Newton MessagePad 120 and an iPhone 12.  iWork update brings new features to Pages, Numbers, and Keynote with version 12.1. Picks of the Week Alex's Pick: Craiyon Andy's Pick: Tot Rene's Pick: Moment Anamorphic Adapter Hosts: Alex Lindsay, Rene Ritchie, Andy Ihnatko, and Mikah Sargent Download or subscribe to this show at https://twit.tv/shows/macbreak-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: nomadgoods.com/MACBREAK onepeloton.com go.newtek.com/twit-tv

Mobile Tracking, Safari's WebKit, NBA All-World  Base 13-Inch MacBook Pro with M2 chip appears to have significantly slower SSD speeds.  US senators ask FTC to investigate Apple and Google over mobile tracking.  Russia threatens Apple with fines for not storing user data within the country.  U.S. Supreme Court won't hear Apple's bid to revive Qualcomm patent challenges.  How refactoring code in Safari's WebKit resurrected 'zombie' security bug.  Uyghur Forced Labor Prevention Act - enforcement begins.  Apple Watch Series 8 rumored to feature new Low Power Mode.  Apple readies iPhone 14 and HomePod upgrade in flood of new products.  AirPods Max beta confirms higher quality Bluetooth codec.  AirPods Pro 2 case redesign with rumored Find My feature shown off in leak, earbud appearance unchanged.  Pokémon Go makers take on basketball with NBA All-World.  For All Mankind' prop fused an Apple Newton MessagePad 120 and an iPhone 12.  iWork update brings new features to Pages, Numbers, and Keynote with version 12.1. Picks of the Week Alex's Pick: Craiyon Andy's Pick: Tot Rene's Pick: Moment Anamorphic Adapter Hosts: Alex Lindsay, Rene Ritchie, Andy Ihnatko, and Mikah Sargent Download or subscribe to this show at https://twit.tv/shows/macbreak-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: nomadgoods.com/MACBREAK onepeloton.com go.newtek.com/twit-tv

Mobile Tracking, Safari's WebKit, NBA All-World  Base 13-Inch MacBook Pro with M2 chip appears to have significantly slower SSD speeds.  US senators ask FTC to investigate Apple and Google over mobile tracking.  Russia threatens Apple with fines for not storing user data within the country.  U.S. Supreme Court won't hear Apple's bid to revive Qualcomm patent challenges.  How refactoring code in Safari's WebKit resurrected 'zombie' security bug.  Uyghur Forced Labor Prevention Act - enforcement begins.  Apple Watch Series 8 rumored to feature new Low Power Mode.  Apple readies iPhone 14 and HomePod upgrade in flood of new products.  AirPods Max beta confirms higher quality Bluetooth codec.  AirPods Pro 2 case redesign with rumored Find My feature shown off in leak, earbud appearance unchanged.  Pokémon Go makers take on basketball with NBA All-World.  For All Mankind' prop fused an Apple Newton MessagePad 120 and an iPhone 12.  iWork update brings new features to Pages, Numbers, and Keynote with version 12.1. Picks of the Week Alex's Pick: Craiyon Andy's Pick: Tot Rene's Pick: Moment Anamorphic Adapter Hosts: Alex Lindsay, Rene Ritchie, Andy Ihnatko, and Mikah Sargent Download or subscribe to this show at https://twit.tv/shows/macbreak-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: nomadgoods.com/MACBREAK onepeloton.com go.newtek.com/twit-tv

Mobile Tracking, Safari's WebKit, NBA All-World  Base 13-Inch MacBook Pro with M2 chip appears to have significantly slower SSD speeds.  US senators ask FTC to investigate Apple and Google over mobile tracking.  Russia threatens Apple with fines for not storing user data within the country.  U.S. Supreme Court won't hear Apple's bid to revive Qualcomm patent challenges.  How refactoring code in Safari's WebKit resurrected 'zombie' security bug.  Uyghur Forced Labor Prevention Act - enforcement begins.  Apple Watch Series 8 rumored to feature new Low Power Mode.  Apple readies iPhone 14 and HomePod upgrade in flood of new products.  AirPods Max beta confirms higher quality Bluetooth codec.  AirPods Pro 2 case redesign with rumored Find My feature shown off in leak, earbud appearance unchanged.  Pokémon Go makers take on basketball with NBA All-World.  For All Mankind' prop fused an Apple Newton MessagePad 120 and an iPhone 12.  iWork update brings new features to Pages, Numbers, and Keynote with version 12.1. Picks of the Week Alex's Pick: Craiyon Andy's Pick: Tot Rene's Pick: Moment Anamorphic Adapter Hosts: Alex Lindsay, Rene Ritchie, Andy Ihnatko, and Mikah Sargent Download or subscribe to this show at https://twit.tv/shows/macbreak-weekly. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: nomadgoods.com/MACBREAK onepeloton.com go.newtek.com/twit-tv

In this month's edition of AppleVis Unleashed, Thomas Domville, Randy Rusnak, and Mike Malarsie discuss recent Apple news and other topics of interest. Topics featured in this podcast include:Grandma's voice from Amazon Alexa is freaking out the internet (00:06:40)Post Discussion of the WWDC 2022 (00:13:12)Ready or Not Here Comes the USB-C (00:22:14)Apple is Getting in to the Sports in a Big Way (00:31:25)What's Coming to the iOS 16 Part 1 (00:34:45)What's in this month AppleVis News (01:08:59)Links:Grandma's voice from Amazon Alexa is freaking out the internetHere's everything Apple announced at WWDC 2022AppleVis Extra #86: Recapping Apple's WWDC 2022 KeynoteEU making USB-C mandatory on all new smartphones from 2024, including iPhoneUSB-C iPhone mandate could bring the US in line with the EUNew AirPods Pro rumored to feature Find My support, USB-C, heart rate detection, improved sound, and moreApple TV to Be Exclusive Home of Major League Soccer Starting in 2023No Apple deal with NFL for streaming Sunday Ticket yet, CNBC reportsMerlin Bird IDWatchTubeAMEROUS 1-4 Players Shut The Box Dice GameYou can email the Unleashed team with feedback or questions at unleashed@applevis.comAlternatively, you can leave a voice message for the team by calling 1-816-774-1668 (note that this is a United States number, so call charges may apply depending upon your call plan and location).

Experimentalism/Ursula Le Guin roundtable: The Keynote From Os Keyes, University Of Washington. June 2022

By around 2044, the U.S. will become a majority-minority nation. This seismic demographic shift has triggered a cultural earthquake, provoking a radical spike in hate crimes. In times of massive disruption and economic stress, what Carl Jung called the “shadow side of the psyche” comes into play: the pronounced psychological tendency in the collective psyche is to project these shadow qualities with unusual potency onto whomever people see as “the other.” But is there also a deeper story? Perhaps the question to ask is: Who benefits? In this half hour, we hear from Heather McGhee of Demos. She sees a direct connection between today's extreme inequality and this peak moment of racial panic and white anxiety. Resources Video of Heather McGhee's Keynote speech at Bioneers 2017 This is an episode of the Bioneers: Revolution from the Heart of Nature series. Visit the radio and podcast homepage to find out how to hear the program on your local station and how to subscribe to the podcast.

Why should I listen to you? Today, join Alex (@AlexHormozi) as he shares one of his favorite Keynote speeches about how he was able to grow over a million followers in his audience within six months through tactical advice and practices in creating content. This is part 1 of the talk. Welcome to The Game Podcast where we talk about how to get more customers, make more profit per customer, and keep them longer, and the many failures and lessons we have learned along the way to $100M in sales. We've got roll-up-your-sleeves kind of hustle with a little bit of cleverness and a lot of heart. Timestamps: 3:30 - Alex shares a quick background on himself and begins with Module 1 of the talk: “Why did I do this to begin with and why you might think it's a good idea” 9:22 - The beginning of Alex's YouTube and content creation journey  15:15 - Module 2: How invested do you need to be in creating content and the content creation model: Test, Record, Inject, Contextualize, & Distribute 23:08 - Observations after putting the content creation model into practice Follow Alex Hormozi's Socials: https://www.linkedin.com/in/alexanderhormozi (LinkedIn ) | https://www.instagram.com/hormozi/?hl=en (Instagram) | https://www.facebook.com/alex.hormozi (Facebook) | https://www.youtube.com/c/AlexHormozi (YouTube ) | https://twitter.com/AlexHormozi?s=20&t=J9vPh75tO3ow9xExYLsBDQ (Twitter) | https://www.acquisition.com/ (Acquisition )

Eheti adásunkban egy kis bosszankodással kezdünk a fotótechnikai fejlesztések és a képfeldolgozó szoftverek miatt, utána pedig beszélgetünk a titánium Leicáról. Benedek mesél a két Todd Hido könyvből merített inspirációiról, végül Peti story-ja kapcsán feldolgozzuk a belemosolygás témakörét. Az adás linkje: https://tripodcast.hu/79 Műsorvezetők: Láng Péter, Lénárt Gábor, Varga Benedek Csatlakozz a Tripodcast Community Facebook csoporthoz! http://tripodcast.hu/community Küldj nekünk hangüzenetben kérdést! http://tripodcast.hu/messages Az adást a Tripont, a Manfrotto, a Fujifilm, a Samyang, a NiSi, a Velbon és a Hähnel támogatta! Egyéni oktatásról az alábbi linken kaphattok információt: https://tripodcast.hu/oktatas Kövess minket Instán: https://www.instagram.com/tripodcast_ Támogass minket Patreonon: https://tripodcast.hu/patreon Az adásban elhangzott témák, linkek: - Arri 35 Keynote: https://youtu.be/ovUL2i--3-o - Leica M-A Titanium https://leica-camera.com/en-int/photography/cameras/m/m-a-titan-set - Leica 0-Series Oscar Barnack: https://www.leitz-auction.com/auction/en/auktion34/auction40/article/305.html - Todd Hido: Intimate Distance: https://aperture.org/books/intimate-distance-twenty-five-years-of-photographs-a-chronological-album-hardcover/ - Todd Hido on Landscapes, Interiors, and the Nude: https://aperture.org/books/educational/todd-hido-on-landscapes-interiors-and-the-nude/

Stephanie Schorp ist Diplom-Psychologin und gilt als eine der renommiertesten Headhunterinnen Deutschlands. Sie ist Mitgeschäftsführerin der Personalberatung “Comites perfect placements” und beschäftigt sich seit über 20 Jahren mit der Auswahl und Beurteilung von Führungskräften. Als Zen-Leadership-Trainerin und über ihre Beratungsplattform „Philosophy meets Management“ setzt sie sich dafür ein, Leadership und Management von morgen besser zu gestalten. In ihrem Buch “Persönlichkeit macht Karriere” erklärt sie, welche Weichen zu einem erfüllten Berufsleben führen und wie man es schafft, den eigenen Weg und die Berufung zu finden. Worum geht's in dieser Folge? Es geht um tropische Nächte in München, Retreats für Frauen und Zen-Meister auf Management-Veranstaltungen, Schwierigkeiten und Methoden, endlich in die Stille zu kommen, Stephanies erste Keynote bei EMOTION's erster Job-Konferenz "re:work", Herausforderungen der moderne Frau, Karriere, die Notwendigkeit, unbequeme Fragen zu stellen, Kooperation statt Konkurrenz, den Sisterhood-Gedanken leben und pflegen, Klischees im Job, die richtig nerven, böse Besen und taffe Frauen, die mal eben den ganzen Laden umkrempeln, Ehrlichkeit, den Balanceakt, authentisch zu sein, aber nicht alles von sich Preis zu geben, glatte Lebensläufe und die Chance, als Quereinsteiger:in aufzuholen, tagesformabhängige Vor- und Nachteile, eine Generation, die völlig anders arbeiten will, energetische Niveaus, Freimachen, eine Aufgabe im Leben zu finden und was wohl Stephanies letzte Gedanken auf dem Sterbebett wären. Stephanie verrät in dieser Folge, was Zen mit Leadership zu tun hat, was "Karriere" heute für sie bedeutet und wie wir herausfinden, was uns erfüllt, wie wir authentischer im Job werden und wann wir vorsichtig sein sollten, die wichtigsten Eigenschaften, um in Zukunft erfolgreich zu sein, auf welche Fallen besonders Frauen in Bewerbungsgesprächen achten sollten und welche Klischees über Frauen immer noch Thema sind, ob sich mittlerweile etwas in den deutschen Vorständen geändert hat, ob die Welt eine bessere wäre, wenn alle das tun können, was sie wirklich wollen und wie wir uns im Job nicht entmutigen lassen. Stephanie findet ihr hier: https://www.instagram.com/stephanie_schorp/?hl=de, https://www.linkedin.com/in/stephanie-schorp/?originalSubdomain=de, https://comites.com/, https://www.philosophymeetsmanagement.com/

 Zu Stephanies Buch gehts hier. Ihr wollt mit uns connected bleiben? Dann folgt uns auf Instagram, Facebook, LinkedIn, Twitter, Pinterest oder abonniert unsere Newsletter.

Housing, the award-winning Chartered Institute of Housing's annual conference and Europe's largest housing festival, returns to its usual timeline and will take place 28-30 June at Manchester Central. When and where is it on? Housing 2022 28th-30th June 2022 Manchester Central, Convention Complex, Windmill Street, Manchester, M2 3GX How many years has it been going? Housing has taken place for 70 years in the UK. Housing 2022 is the biggest event in the housing calendar. What exciting things can people look forward to? 10 theatres, 450+ speakers, 8000+ attendees and 300+ sponsors and exhibitors over the three days – it is the biggest meeting place for the whole housing sector. Housing 2022 is covering the economic landscape, building safety, homelessness, housing delivery, affordability, funding, and lots more relevance to everyone working in UK housing. The event also covers all the key developments in technology for housing such as IoT, AI, digital transformation, self-service, low-code and much more. Discover new technology emerging in the sector with many #Tech4Good themed products launching. What opportunities are on offer for those attending? Apart from covering the economic landscape, building safety, homelessness, housing delivery, affordability, funding, climate change and lots more relevance to everyone working in UK housing, those attending the event will get the opportunity to meet their key government departments. They will also get a chance to network with over 8000 attendees and participate in roundtable sessions. Who will be speaking? Speaker list, click to expand: Speaker List The Rt Hon Stuart Andrew MP John Barnes MBE Social housing ambassador Kinetic Developments Ltd Darren Baxter Policy and partnerships manager (housing) Joseph Rowntree Foundation Lord Richard Best Member House of Lords of the United Kingdom Scott Black Executive director – development Places for People Richard Blakeway Housing Ombudsman Housing Ombudsman Service Yvonne Castle Chief executive Johnnie Johnson Housing Cecily Church Sustainability manager The Guinness Partnership Matt Downie Chief executive Crisis Amy Varle Social housing ambassador Socially Homes Steve Ellard Director of assets & sustainability Yorkshire Housing Catherine George Neighbourhood Management Officer South Liverpool Homes Neil Goodrich Business insight manager (corporate planning) Orbit Kate Henderson Chief Executive National Housing Federation Martin Hilditch Editor Inside Housing Steve Hoey Chair Community Land Trust Network How to get the most out of Housing 2022? The Chartered Institute of Housing has requested attendees to get to the event early and make the most of the networking opportunities available there. They also requested those attending to get social online on the many different platforms, and use hashtags #Housing2022 – #SociallyHomes – #LetsGetSocial to get a chance to meet some of their online connections in person at the event. How can people book tickets? Tickets and prices can be found here: Access all areas with a delegate pass The best way to attend Housing is with a delegate pass, giving you access to all aspects of the exhibition and conference agenda, including the Keynote theatre, Housing Management theatre, Masterclass theatre and Future of Living theatre. Register for free visitor pass Visitor passes will give attendees access to the show floor and networking areas including: 6 stages of CPD award-winning content including the award-winning Fringe Festival stage, Knowledge and Insight stages and PfH Live. The climate change hackathon Breakfast briefings including large-scale estate regeneration and joint-ventures to boost delivery A book launch with leading architects BEIS Wave 2 funding workshop Numerous networking opportunities and drinks receptions Visitor passes are free to housing associations, local authorities, public sector, housebuilders, master developers, funders, architects, planners and BTR landlords, student accommodat...

Reggie Fils-Aimé is an award-winning innovator and disrupter most recognized as the retired President and Chief Operating Officer of Nintendo of America (NOA), the largest division of the Japanese entertainment company Nintendo Co., Ltd. (NCL). In this capacity, he helped bring Nintendo's greatest successes to the global marketplace. Reggie was the first American and African American to be President of NOA, and the first American and African American named as an Executive Officer of NCL. He retired in April 2019 and was inducted into the International Video Game Hall of Fame later that year. Before Nintendo, Reggie had a successful career spanning consumer-packaged goods, restaurant, beverage, and media/entertainment industries. Since retiring, Reggie has focused his energy on cultivating the next generation of business leaders. In August 2019, he was named Cornell University's Dyson Undergraduate Business School's inaugural Leader in Residence where he instructed students on leadership and innovation. Reggie also founded Brentwood Growth Partners to help emerging companies scale and enable leaders to create world-class cultures. Reggie currently is a non-executive director for Spin Master Inc. (TOY.TO), and Brunswick Corp. (BC). He is also a special advisor for Rogue Co., an innovative video games publisher and developer. Most recently, Reggie was named Chairman of the Board for a special purpose acquisition company (UTA Acquisition Corp.) focused on gaming and its adjacency markets.

I gave the keynote for the NJTESOL conference on June 3rd. This is that talk

Man oh man, what a mighty good man! Y'all!!! How did we get so lucky? Keynote speaker, Nic Frank, dazzled on stage this weekend, AND somehow made time to visit with us on the mics. It was an absolute delight getting to know him and making a super cool new friend!

In this episode, Bryce and Conor talk about Bryce's ARRAY 2022 Keynote talk, mdspaces and more!TwitterADSP: The PodcastConor HoekstraBryce Adelstein LelbachShow NotesDate Recorded: 2022-06-13Date Released: 2022-06-24PLDI 2022ARRAY 2022Bryce's ARRAY 2022 Keynote Talk (not online yet)Conor's ARRAY 2022 Talk (not online yet)C++23 std::mdspanC++23 std::mdarrayC++23 extentsArrayCast Episode 28: Rank and Leading Axis TheoryArrayCast Episode 29: TransposeJ |. (transpose)Dyalog APL ⍉ (transpose)BQN ⍉ (transpose)All PowerPoint ShortcutTools 3.0 Keyboard ShortcutsPowerPoint Morph TransitionReddit: CPP Cast is over, what are you all listening now?CppCast Podcastcpp.chat PodcastNDR PodcastTLB hit

View in HD at . A new feature in Keynote lets you easily place an animated dynamic background behind your slides. You can customize them with your own colors, sizes and movement.

The latest In Touch With iOS with Dave he is joined by guest Andrew Orr, Jeff Gamet and Warren Sklar. We discuss some of the great articles Andrew wrote including the 6 iOS16 you won't see in the fall, Apple might eliminate Captcha with private access tokens, and more. iOS 16 beta 2 was released with many more new features including screenshots that can be added to a Quick note.New Apple Watch app called WatchTube where you can watch videos on the Watch. Plus much more.  The show notes are at InTouchwithiOS.com 
Direct Link to Audio Links to our Show Click this link Buy me a Coffee to support the show we would really appreciate it. intouchwithios.com/coffee  We have a brand new way to support the show become a Patreon member patreon.com/intouchwithios Website: In Touch With iOS YouTube Page In Touch with iOS Magazine on Flipboard News Nintendo to end Switch Online app support for older iPhones and iPads Volkswagen CEO questions Apple Car future as Polestar ships OTA CarPlay and promises next-gen adoption Andrew wrote: When Apple announced the new CarPlay that would fill the entire dash in a car you wonder what automakers would partner with Apple. Apple's 2023 CarPlay is an Apple Car preview - and is scaring Detroit iWork update brings new features to Pages, Numbers, and Keynote with version 12.1 Man recovers iPhone lost at the bottom of a river for 10 months Swimmer stuck in frigid Columbia River uses Apple Watch to call for help T-Mobile: Being sued by AT&T, Verizon customers for increased prices Topics Beta this week. iOS 15.6 Beta 3 and iOS 16 Beta 2 are both running. 15.6 should be released soon. Apple Seeds Second Betas of iOS 16 and iPadOS 16 to Developers Some new features added to iOS 16 iOS 16 Beta 2 Tidbits: New Wallpaper Colors, Backup Over LTE, SMS Filtering and More Apple Seeds Second Beta of watchOS 9 to Developers Apple Seeds Second Beta of tvOS 16 to Developers Apple Watch Series 4 and 5 Will Recalibrate Maximum Battery Capacity With watchOS 9 Apple Confirms iPad Will No Longer Be Supported as a Home Hub in iOS 16 iOS 16 and macOS Ventura Add Support for Verified Brand Logos in Mail App Apple's Junk Message Reporting Now Covers SMS for Select US Carriers in iOS 16 iOS 16 Beta 2 Adds Support for Backing Up Over LTE iOS 16 beta 2 now resends edited messages to users running previous versions of iOS Andrew had some great articles over at AppleInsider these past few weeks we thought we would discuss these topics.  You had to know that there will be some features that were announced for iOS 16 that would not be ready. Six features that users won't see in iOS 16.0 this fall Many apps were running on the web instead of a standalone app. Apple's relationship with web apps will improve in 2023 We all do not like those captchas you need to type in to get past security on a web site. Apple could kill this with access tokens.  How Apple could kill CAPTCHAs with Private Access Tokens Apps Jeff recommends this app. Linea Sketch on the App Store A new app just for the Apple Watch where you can watch YouTube videos, Watch YouTube videos on your Apple Watch with WatchTube Our Host Dave Ginsburg is an IT professional supporting Mac, iOS and Windows users and his wealth of knowledge of iPhone, iPad, Apple Watch, and Apple TV. Visit the YouTube channel https://youtube.com/daveg65 follow him on Twitter @daveg65.and the show @intouchwithios Our Regular Contributors Jeff Gamet is a podcaster, technology blogger, artist, and author. Previously, he was The Mac Observer's managing editor, and Smile's TextExpander Evangelist. You can find him on Twitter and Instagram as @jgamet and YouTube https://youtube.com/jgamet Warren Sklar @Wsklar is an IT Consultant and moderator of the Mac To The Future FaceBook Group with over 3000 members talking about all things Apple. Request to join this group to be among people who love Apple. About our Guest Andrew Orr  is a writer for appleinsider.com and an amateur photographer. He loves Apple products and enjoys writing and sharing all things tech. When he's not writing about Apple, you can often find him snapping photos with his iPhone. You can find him on Twitter @andrewonot.

Enjoy!

Dr. Diwakar Davar and Dr. Jason Luke, both of the University of Pittsburgh's Hillman Cancer Center, highlight key advances in early phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting and also address toxicities, including immune checkpoint inhibitor-associated myocarditis. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. My name is Dr. Diwakar Davar, and I'm an assistant professor of Medical Oncology, specializing in melanoma and phase 1 therapeutics at the University of Pittsburgh's Hillman Cancer Center. I am the guest host of today's podcast. My guest today is Dr. Jason Luke, a colleague and the director of the Cancer Immunotherapeutics Center at the UPMC Hillman Cancer Center here.  Today, we'll be discussing advances in early-phase therapeutics and immunotherapy that were featured at the 2022 ASCO Annual Meeting.   You'll find our full disclosures in the show notes, and the disclosures of all guests on the podcast are available on our transcripts at asco.org/podcasts.  Jason, thank you for coming on the podcast today.  Dr. Jason Luke: Thanks so much for the invitation. It was a great ASCO, and I hope everyone had a good time.  Dr. Diwakar Davar: So, onto our abstracts. So, the first one that we'll be discussing, and Jason as you know we've done this before. We'll be rapidly transitioning between phase 1 therapeutics, melanoma, and advanced phase 2 and 3 trials, but you know this is something you do very well. So Abstract 2504, it's a phase 1 trial of TIM-3 inhibitor cobomilab immunotherapy and in combination with PD-1 inhibitors nivolumab and dostarlimab. The AMBER Trial that was presented recently, and in full disclosure, both you and I actually are on this abstract. So, what do you think of this abstract? What do you think of the data that is discussed, and how do we contextualize this in relation to what needs to be done in this space?  Dr. Jason Luke: So, I think this is an exciting abstract because it brings forward what may be the next high-priority immune checkpoint to try to target in clinical oncology. To level-set, I think everybody listening will know about PD-1 and CTLA-4 as immune checkpoints. In the last year, we've had LAG-3 come forward as now a standard of care element of armamentarium in melanoma, and we look forward to further studies of LAG-3 and other tumor types as we think it should be a good partner where PD-1 is otherwise approved.  So here now, we hear about TIM-3, which is another negative regulatory checkpoint on a number of different immune subsets. And in this abstract, the antibody targeting TIM-3 was cobolimab. So, TIM-3 is a very interesting molecule. It has, what you might call, pleiotropic effects in the immune system. So, while in the context of this abstract, it was being targeted as another immune checkpoint on T cells, it's important to point out that TIM-3 has other regulatory roles in other immune subsets such as myeloid cells and very particularly dendritic cells, and that's important because it might bring in another element of the innate immune system to try to drive anti-tumor responses. So, it's an exciting target because it might be able to expand the groups of patients who could benefit from immune checkpoint blockade.  So, in this abstract, we see initially the phase 1 data of combining cobolimab, anti-TIM-3 with anti-PD-1 of a couple of different flavors. And what you could take from this abstract is that in the phase 1 setting, the drug was well-tolerated and combined well, and had pharmacokinetic properties that would be consistent with what we'd expect for this kind of a monoclonal antibody. I think we have to marry this abstract, which is really the phase 1 data about safety in pharmacokinetic (PK) to another abstract presented in the melanoma session, which showed an expansion cohort of patients who got cobolimab plus nivolumab or dostarlimab.  And there we did see a 50% response rate, albeit that there was heterogeneity of patients being treatment naïve versus treatment-experienced. So, what I would say to this on a high level is that I think these data are preliminarily exciting, suggesting that further investigation into TIM-3 may be valuable in terms of expanding the population of patients initially in melanoma, but there will data coming soon in lung cancer and in other tumor types with another novel checkpoint. And I think if we think ahead into the future, the question is probably going to end up being, which combinations of checkpoints for which patients. That's pretty exciting to think about. We've seen a lot of data of PD-1 plus other molecules, and I think some future biomarker stratification really will be necessary to know which patient would benefit the most from which of these combos, but for the time being, this is exciting data to see where the field is going to go over the next couple of years.  Dr. Diwakar Davar: Great. And I guess, to your point, one important thing to highlight from the abstract is your point about the role of the different compartments. There was actually a very interesting dose-response relationship with the highest dose of the drug not necessarily being the most effective dose, suggesting that yes, as you escalate, you may have different effects in different compartments, and maybe therefore a broad selection of doses might be required to ensure that you have optimal engagement of the optimal target.  So, the next abstract is Abstract 3007. This is the tumor-agnostic efficacy and safety of erdafitinib. So, we now know that FGFR pathway aberrations are found from 77% of all malignancies, FGFR targets are now U.S. Food and Drug Administration (FDA) approved in cholangiocarcinoma with pemigatinib, infigratinib, and as well with erdafitinib metastatic urothelial cancer. We know that these agents are not necessarily effective tests in 1 tumor type because these alterations have risen in multiple tumor types. So, the RAGNAR trial, looking at this across multiple tumor types, what do you make of the interim analysis result presented by Dr. Loriot?  Dr. Jason Luke: So, I'd say that this is probably the future of targeted therapy. And so, I think that where we have activity in 1 disease, it's very likely we would have activity in others. So, the author has described this as the largest basket trial of a molecularly defined subset that's been pursued to date. There are upwards of more than 200 patients in the study. I think it's really important, as we think about the data, to realize, though, that all FGFR alterations are not exactly the same thing. And so, in this study, they gave erdafitinib to patients with solid tumors of any FGFR altered status. And so that's FGFR1, 2, 3, 4 mutations or gene fusions. And that's a lot of heterogeneity in there actually.  And in this study, there were two-thirds fusions and one-third mutations, mostly in FGFR2 and 3. That will become relevant as we start to think about the results. On a high level, I have to say that it is impressive in pan-cancer fashion, just selecting by FGFR alteration, there's about a 30% response rate observed. I think that no matter what, that's going to be valuable considering these were patients with refractory tumors with 3 lines of prior therapy on median. I think what we need to know more is the breakdown of which specific molecular alteration and FGFR in which tumor types drove most of the benefit.  So, for example, in bladder cancer where erdafitinib is already approved, that's almost entirely an FGFR3 fusion setting. So we know the drug is effective there. And so I think there will be a further breakdown of the data. As it matures more, you really start to tease out, is it really the case that any FGFR alteration can be treated or there are some that really ought to be the high priorities that we really ought to be going after. I think it would be remiss not to also note, however, that while there's excitement about this sort of pan-cancer approach, the current generation of FGFR inhibitors are not exactly the easiest drugs to take.  And so, the in-class, hypophosphatemia and stomatitis really does lead to dose reductions in a lot of the patients. And I think that that's probably really important to emphasize is that despite the pan-tumor activity, there's still a lot of potential in this field to refine further because it's almost certainly the case that if we had less off-target toxicity, so to say, we could improve the efficacy beyond that 30% that we saw here.  All the same, I think this is exciting for the concept of a pan-cancer tumor agnostic sort of approach, and we'll really look forward to more data to come from this study over the next, hopefully, few months.  Dr. Diwakar Davar: And I guess 1 corollary to that is that we now need to start looking for FGFR alterations in multiple tumor types. So, tests, tests, tests. All right, Abstract 3004, phase 1a/1b dose escalation and expansion study of the MDM2-p53 antagonist BI 907828 in patients with multiple solid tumors including advanced, metastatic, liposarcoma. So, we've recently had data of the previously undruggable KRAS, and now we've got previously undruggable p53, for which we now have targets. So, Jason, what do you make of the p53 targeting approach, in this case, using MDM2 and this particular drug from Boehringer Ingelheim?  Dr. Jason Luke: So, I think that this is an exciting abstract exactly for the reason that you mentioned, which is that p53 has been, and unfortunately, to some degree, still remains, one of those holy grails but undruggable targets in oncology. So MDM2, for those who are listening but might not be aware, is a negative regulator of p53. So, the concept here then is if you drug it, you might release p53 to reactivate activity in that pathway, and then p53 being the guardian of the genome, so to say, potentially leading to apoptosis of cancer cells.  And so, this drug binds MDM2 and MDM2 can be amplified as a resistance mechanism in p53 and several tumor types. And so here, they showed data for the early part of a clinical trial investigating the small molecule, BI 907828, but then they focus specifically in liposarcoma, which is a disease known to be an MDM2 amplified. And so, the results were pretty interesting. The toxicity of this kind of an approach, just to note, is really in class. It leads to some gastrointestinal (GI) toxicities as well as hematologic problems, and this goes again for most regulators of the cell cycle will have these effects, whether they're CDK inhibitors or MDM2 or p53 modulators.  But I think what was very interesting, this is a disease liposarcoma where chemotherapy, functionally speaking, has no role. We, unfortunately, give it to some patients sometimes, but it has almost no activity, and they observe that in poorly differentiated liposarcomas, the response rate was about 12%, but the stable disease was quite durable. And so, I think that really is potentially a big deal because this is an orphan disease. It really lacks any other treatment. But as you zoom out from that, if you start to think about targeting amplified MDM2 in other settings, I think the activity that we see here is intriguing, and potentially suggests that we may be coming to a future where we'll have multiple, sort of, orthogonal approaches after reactivating p53. There were actually other abstracts at ASCO Annual Meeting of other molecules that were less mature also along this line.  So, I think, very exciting to take away from this, one, a potential treatment for liposarcoma for all of those patients that anybody listening actually sees, but secondarily this concept of targeting p53, which I think we'll see a lot more of over the next couple of years.  Dr. Diwakar Davar: Excellent. Moving on to the Abstract 3002, this is a phase 1, two-part multicenter, first-in-human study of DS-6000a of an antibody-drug conjugate comprising the anti-CDH6 IgG1 monoclonal antibody that is attached to a topoisomerase I inhibitor payload via a cleavable linker. And so basically, a way in which you can give topoisomerase: (1) TOP1 inhibitor, (2) CDH6-expressing cells. This was studied in advanced renal cell carcinoma (RCC) and advanced ovarian cancer in this abstract presented by Dr. Hamilton. Jason, what do you think of the results and what do you think of this approach in general, this antibody-drug conjugate (ADC) approach using novel targets as well as novel payloads?  Dr. Jason Luke: I think this is one of those that you can't help but be pretty excited about, and I think in the context of the data shown at the plenary session in breast cancer for antibody-drug conjugates (LBA3), I think this is really where the field is going to start to go. So, you mentioned that this is an antibody-drug conjugate that targets cadherin 6 or CDH6, which people will remember from biochemistry class and medical school, or something is a cell-cell adhesion molecule, really a basement membrane protein. So, the concept of targeting it really is just to go after a latch mechanism to get the molecule into the tumor where you want. And CDH expression is very high in renal cell carcinoma, upwards of 80% of samples, also high in ovarian cancer, which is why they chose those 2 tumors to go after.  So, the ADCC, and you described its structure just a little bit, but it's essentially the same backbone as trastuzumab deruxtecan, which we saw this outstanding activity for HER2 and breast cancer on the plenary, with these 8 chemotherapies moieties attached to it, but here now, targeting it instead to HER2, with this molecule now to CDH6. And I think, again, you can't help but be impressed. There were treatment responses on almost every dose level of the dose escalation in this study. There's in fact only 1 patient whose tumor was not, at least, stable disease or a PR, and I think that that just goes to show the power of truly bringing the chemotherapy in a targeted manner into the tumor microenvironment. Responses were heterogeneous. They were not super deep responses per se, but the stable disease was quite durable in the study, and the patients were going out more than 7 months. And again, realizing this is at the lower dose levels as we're increasing the dose and move this in their earlier lives of therapy is likely to be even more effective.  They did show a waterfall plot of the reduction in CA 125 for the patients with ovarian cancer that really looked quite impressive. And given that that's our clinical biomarker that we commonly follow, it may actually even more indicative of the benefit we would see as opposed to resist.  Now, again, there is some toxicity. It is a chemotherapy moiety that's conjugated to the ADCs. So, the most common toxicities were nausea, vomiting, and low platelet counts, but these are kind of toxicities that we're quite accustomed to with chemotherapy. Just to summarize, I think there's a lot of promise for this kind of antibody-drug conjugate targeting, and I think it can only be impressive that they had this amount of activity in the dose escalation of the study. [I] very much look forward to the expansion cohorts in renal and ovarian, which we'll presumably expect to see later this year, early in the next year.  Dr. Diwakar Davar: And as you alluded to, this really was parallel that ASCO, by the standing ovation given to Dr. Modi when she presented the DESTINY04 data of trastuzumab deruxtecan in HER2-low breast cancer, basically now redefining breast cancer from 4 camps, now we have to think of not just HER2 amplified or HER2-high, but also HER2-low. So yes, really have to now rethink how we classify these diseases (LBA3).  So Abstract 2509, the efficacy of anti-PD-1/PD-L1 immunotherapy in non–small cell lung cancer dependent based on CD8 and PD-L1 status. So really Dr. Galon taking us into what he has now described as the immunoscore—really a way of characterizing tumors. A way of thinking about tumors that you've also championed, Jason, in terms of this T cell-inflamed and uninflamed hypothesis. So, tell us a little bit about how these jives with your work and how you would think about lung cancer patients responding and not responding to immune checkpoint inhibitors (ICI) therapy in this context?  Dr. Jason Luke: Yeah. I think the focus quickly here on the immunoscore, so the people are aware of that, I think is really important for diving into these specific results. You have to realize our fundamental underlying predicate for immune checkpoint blockade inhibitor response is that patients have mounted an adaptive immune response. So, CD8 T-cells have gone into the tumor where they elaborate chemokines and cytokines like interferon gamma, which upregulates the expression of PD-L1 in the tumor but also in the surrounding immune cells.  So, you realize that even though antibodies are targeting PD-1, it's really that we're targeting that tumor microenvironment. So, the more robustly we can measure that, and we understand it, the more likely we are to know whether or not the patient is going to benefit. So, this is where the immunoscore comes in. The immunoscore is actually a fairly simple test. It's one slide, immunohistochemistry slide where they can stain jointly for CD8 and PD-L1 on the same slide. And that allows them to do a number of different things beyond just testing the total level of PD-L1. They can test the CD8 density, the PD-L1 expression, but then also the interaction between CD8 T-cells, their distance from each other, from PD-L1 expressing cells, and so on and so forth.  And so really [this] can give us a much more robust analysis of what all is going on in the tumor microenvironment again, off of a single slide. So here then, in this abstract, for patients with non–small cell lung cancer receiving anti-PD-1, they then compared the utility of only PD-L1 testing versus doing the immunoscore. And so, it was actually quite a large set. They had about 250 patients in their analytical set and then split about 150 or 180 or something into the training and validation sets, and they compared the immunoscore against 2 different standard PD-L1 antibodies, the 22C3 as well as the SP263. And what they saw was a high concordance for expression between PD-L1 and the immunoscore.  That's good, because, again, they're measuring PD-L1 in both of those. And so that was a good, sort of, level set. The immunoscore, however, allows them to look to 7 different parameters, again, beyond just PD-L1, as I mentioned. So, CD8 density, interaction, distance, and this kind of thing. Then in these test and training cohorts, they were able to actually split out patients who are PD-L1 positive into further groups, those that were immunoscore low and that were high. And in so doing, they were actually able to sort of dramatically predict the likely progression-free survival on PD-1 checkpoint blockade in those different non–small cell lung cancer groups.  So why is this important? Selection of patients by PD-1 has been very useful in the field of non–small cell lung cancer, but it's hardly a panacea. You're not at all assured your patient is going to do well just because they're PD-L1. And here comes a second assay that can be done in a standard of care setting. So, the immunoscore is a test. You could just order it, and that really does give you much more predictive power about who's likely to do well and who isn't. And I think this test and more broadly multi-spectral imaging is really going to become a core component to how we risk stratify and predict outcomes to checkpoint blockade and lung cancer, but broadly in other tumor types over the next couple of years.  Dr. Diwakar Davar: Okay. Now, moving on from a biomarker for PD-L1 and PD-1 to a setting in which PD-1 was just recently U.S. Food and Drug Administration (FDA)-approved, so I'll give a brief background to the trial that you've actually developed and led. And so, this is KEYNOTE-716, the abstract in question is LBA9500 (late-breaking abstract) 9500, but this is the distant metastasis-free survival (DMFS) data readout. The DMFS, distant metastasis-free survival with pembrolizumab versus placebo in the adjuvant setting for patients with stage IIB or IIC, that is high-risk node-negative melanoma and the data from the phase 3 KEYNOTE-716 study.  So, this data, at least the recurrence-free survival (RFS) data was actually earlier published, you had presented it earlier last year and also more recently this year, but it was published recently in Lancet. And we know that 716 is a study in which, for the first time ever, we have an immune checkpoint inhibitor PD-1 that was studied against placebo with the high-risk node-negative setting in stage IIB and C melanoma, demonstrated a significant RFS benefit in the setting against placebo. And now we have the DMFS readout.  Maybe you could tell us a little bit about both the RFS and the DMFS data, and why this is such an important advance for these patients.  Dr. Jason Luke: Thanks. And I agree this really is a sea change in how we thought about stratification of patients with melanoma, but I think this broadly has implications for other tumor types as well. So, in melanoma, we've historically thought of its involvement of the lymph nodes—stage III as being the high-risk disease, but we also, if you look at the outcomes from the AJCC, we see the patients with stage IIB and IIC, so deep primary lesions, actually have similar bad outcomes as those patients with stage IIIA and IIIB. And so anti-PD1 and adjuvant therapy and melanoma were originally proved for stage III, but having understood that about 5 years ago actually, started to think, well, why not also treat the patients with stage II if they're at similar risk.  And we pursued KEYNOTE-716 as you mentioned, and it read out last year as a positive trial for recurrence-free survival. And the abstract here then was to look at the impact on distant metastasis-free survival. So, while the regulatory consideration for approval, and it is approved and it's available for patients now, was based on relapse, what we really want to be preventing is the development of metastatic disease because presumably that would correlate with the eventual death of the patient from cancer.  So, in the abstract here, we see the first update for DMFS, which also was positive on its first analysis, the hazard ratio at 0.64. And so, again, very similar to the RFS benefit, showing about a 35-36% reduction in distant metastasis-free survival. And this is a theme that we've seen across adjuvant studies in melanoma, all the adjuvant studies in fact, is that the RFS improvement, the relapse-free survival hazard ratio mirrors very closely the distant metastasis-free survival ratio. We saw that again here. I think it just emphasizes that anti-PD-1 immunotherapy is highly effective in melanoma no matter what stage it's in, but rather related to the risk of death for melanoma.  And so this really has a practice changing in the field of melanoma oncology. Patients need to be referred to medical oncology early for discussion around risk stratification and consideration of adjuvant therapy—I think even at the same time that they're having resection of their primary lesion, and it even calls into  question of whether or not we should even fully be doing procedures like sentinel lymph node biopsies any longer, considering we can make the decision to give adjuvant therapy now based on the primary—albeit that's a controversial area of discussion.  And I would just love for this to start to penetrate into other disease settings. We've seen more recently, approval for neoadjuvant therapy in lung cancer and we see in kidney cancer, bladder cancer. We see adjuvant therapy in—I think we're going to see immunotherapy starting to become an important part of the armamentarium in these hard-to-treat cancers, even at the time that perioperatively before or after surgery.  So definitely a major change in the way we're thinking about stratifying patients and emphasizes that you need to get those patients with melanoma in to have that discussion around adjuvant therapy probably at the time of the primary lesion resection.  Dr. Diwakar Davar: And finally, Abstract 2507, single-cell profiling of human heart and blood in patients with checkpoint inhibitor-associated myocarditis. So, this is data from the NGH Group, Dr. Villani and colleagues are presented by Dr. Blum. We know that myocarditis is an uncommon but very serious immune related adverse event (irAE), and here in this particular dataset, this group which has done a lot of underlying work to really uncover the role of certain key phenotypes, cellular phenotypes, in the development of myocarditis it's presenting the data in the context of ICI-related myocarditis. So, what do you think of this data, what do you think of the use of checkpoint inhibitors are now, as you've said, migrated linear in the lifecycle of the patient, what do we need to be thinking about and how does this improve our understanding of both the use of the drug and what we need to be worried about?  Dr. Jason Luke: I think the toxicities of immunotherapy, while, less frequent than, say, chemotherapy, can actually be more disastrous. In the rare patients, we have extreme immune-related adverse events, there is an incidence of actually life-threatening and fatal events. And so, myocarditis, associated with checkpoint blockade, is one of those things that could be seen, and here at ASCO Annual Meeting, we saw a couple of abstracts summarizing the experience from the National Cancer Institute following myocarditis events, and then this abstract in a translational level trying to better understand what is actually going on in terms of the immune response in those myocarditis cases.  And so, I thought this was actually a very interesting abstract. There was only a small number of patients. They had 13 samples from patients who had had endomyocardial biopsies in the context of immune-related myocarditis, and you might say, well, only 13 samples, but fortunately, this is quite a rare event, less than 1% of patients who get immune checkpoint inhibitors. And what they saw was relatively unsurprising, which is that in patients who were having myocarditis, they saw an increase in T cells and in K-cells, as well as activated CD8 and CD4 T-cells.  I think what was very interesting was when they started to dig into what were the phenotypes of the cells and what were the pathways that were turned on. Again, it was not especially surprising to see that they saw increased levels of interferon signaling and immune-receptor signaling as well as motility and adhesion, but this really, I think emphasizes that there are potentially interventions beyond just the general immune-suppression approaches that we give. They could be more nuanced but perhaps more efficacious because sadly, patients do pass away when they develop this. And in their cohort of 13 patients, 3 of those patients died. And specifically, in looking in those 3 patients, they actually saw that all 3 patients had a shared T cell cluster. And they can't exactly say what it is exactly yet, but I think it's very interesting to see that because it suggests that there's probably something about the T cell response in those patients that disproportionately triggered a fatal event.  And if we can understand that better, we then may be able to really tailor our interventions in a way that is more useful. Because, frankly, the way these patients usually present is they show up in the emergency room (ER), and they're seen by an ER doctor who thinks they're having acute coronary. They ship them off to the catheterization (cath) lab. They open him up, and then they get in there, and there's nothing going on. There's no plaque. And so now, all of a sudden, everyone is quite confused. And so, if we had better ways to search for that ahead of time to be aware of it, we might have better interventions because usually what happens right at that moment is everybody gets very confused and starts calling the oncologist, and we start slapping on steroids and other immunomodulatory agents, but sometimes it's late.  So, I think this is a great abstract. It's really starting to preliminary give us an idea of what is the actual biology that underpins these terrible events, and we can hope that we can build off that over time hopefully to eventually come up with better predictors and then obviously better interventions to try to avoid these outcomes in a small but real number of patients.  Dr. Diwakar Davar: Excellent. One other point is you and I are both involved in drug development, and as we start thinking of side effects. Side effects are really on the flip side of responses in drug development. So really 1 point to make of this is that when people start developing side effects rather than, as you say, putting your hands up in the air and waving them around, 1 of the things that we should be doing in drug development is possibly biopsying these patients because we could get new PD insights into how these drugs work, why they work, and particularly which sub-populations themselves they work on, particularly in the early-drug development setting when you oftentimes don't have that many responses.  With that, thank you, Jason, for sharing your insights with us today.  Dr. Jason Luke: Thank you.  Dr. Diwakar Davar: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So, thank you for your attention, and we will sign out.      Disclosures:  Dr. Diwakar Davar:   Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences  Consulting or Advisory Role: Instil Bio, Vedanta Biosciences  Consulting or Advisory Role (Immediate family member): Shionogi  Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences  Research Funding (Inst.): Zucero Therapeutics  Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy  Dr. Jason Luke:   Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine  Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure  Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)  Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

Some highlights from Linus' recent fireside chat, Qt gets a new leader and a Linux botnet we should probably take seriously.

An interview with Waldo Waldman & Freddie Ravel that originally aired on November 3rd, 2021, as part of Leveraging Thought Leadership Live on LinkedIn. In March of 2020, the keynote speaking business came to a grinding halt.   Before Covid-19, many speakers were predicting a record-breaking year for events and conventions. During the pandemic's height, speakers and live workshops went on hiatus, hoping the shutdown wouldn't last long. But a few visionaries forged new ways forward, using technology and innovation to help them deliver their message. To discuss how keynote speaking changed during the pandemic and where keynote speaking is going in the future, I invited two of the best in the business to join me. Waldo “The Wingman” Waldman is the bestselling author of Never Fly Solo: Lead with Courage, Build Trusting Partnerships, and Reach New Heights in Business, and a member of the Speaker Hall of Fame.  He speaks around the world on the topics of trust and teamwork. Freddie Ravel is a Grammy Award-winning musician who delivers dynamic multimedia “keynote concerts” on leadership, sales, and performance. In this episode, we explore how each of our guests has pivoted their innovative style of keynote speaking to a virtual platform, using video and technology to connect with clients and audiences. Even with huge advancements in technology, speakers will still be faced with the difficulty of proving their value in a virtual setting, in order to maintain price integrity.   Waldo warns that speakers who are not adept with (or willing to learn) new technology are going to be shot down. Freddie explains how he created a custom home setup that allows him to bring messages and music to audiences in a dozen time zones — all at once. We further discuss the way additional products and solutions can give your virtual keynote an advantage, and create momentum that sustains change and creates actionable items for anyone who attends. This is an insightful conversation into the ways that keynoters have sustained and grown their businesses using hybrid models, technology, and innovation. Come and listen — this information is sure to be useful to anyone operating in a speakers' arena. Three Key Takeaways: * When speaking virtually, you need a clear picture of your audience's needs and interests, and an understanding of their pain points, in order to connect with them emotionally. * Regardless of how you deliver your thought leadership speaking, content is king. * Be ready to offer follow-up products and solutions that will ensure your message goes further.

John talks to Kristina Hoyer — former US Navy rescue swimmer, entrepreneur, competitive athlete, yoga teacher, human performance coach, and chronic pain survivor. Having served in the US Navy for six years, Kristina left the service after sustaining a serious injury. Listen to her as she discusses her journey into the US Navy and life as a human performance coach. Listen to this episode to learn more: [01:30] - What made Kristina enter the Navy [08:12] - Kristina's experience in the Navy [11:12] - Her keepsakes from the Navy [13:50] - The reason she left the Navy [17:36] - Internal changes Kristina made so her identity is not tied to what she did/does [22:52] - How John's pain made him what he is today [25:14] - Some of the dangerous ways people pretend pain is not there [28:00] - The difference between happiness and joy [30:00] - About Re-Human coaching [32:21] - What makes her coaching unique [35:35] - Ideal client for Kristina [38:08] - What does a quick win look like  NOTABLE QUOTES: "No one job is who you are and no one thing is who you are like you're not only a mother or a father." "Figure out who you want to be, not what you want to do." "Pain leads to purpose, which leads to the platform." "The problem with most people is that they pretend the pain is not there. And some of the more dangerous ways that people pretend the pain isn't there is by trying to cover it up, putting salve on it, and using things like alcohol, drugs, and promiscuity. And none of those things are healthy because they don't help. All they do is push off what you're going to have to deal with anyway. And the further you push it down, the worse it gets." "Many times, people confuse happiness with joy. Happiness means I feel good about this at the moment because something is driving it at the moment. And as soon as the moment is gone, I am no longer happy. So striving for happiness is fool's gold." "Joy says, even in the midst of the most horrific things that could possibly happen in life, i.e., the Holocaust, I can still be filled with this sense of purpose. Joy is being fulfilled regardless of the circumstances."  "A lot of the time, when you've been living with a certain amount of pain for a long time, you don't necessarily realize how much discomfort you're in." BOOK MENTIONED: 48 Days to the Work You Love: Preparing for the New Normal by Dan Miller (https://tinyurl.com/48DaysBookDM)  USEFUL RESOURCES: https://www.kristinahoyercollective.com  https://www.instagram.com/kristinahoyercollective/  https://www.facebook.com/Kristina-Hoyer-Collective-112781317226104  https://www.linkedin.com/in/kristinahoyer/  CONNECT WITH JOHN Website - https://thejohnhulen.com       Instagram - https://www.instagram.com/johnhulen       Facebook - https://www.facebook.com/johnhulen       Twitter - https://www.twitter.com/johnhulen       LinkedIn - https://www.linkedin.com/in/johnhulen       YouTube - https://www.youtube.com/channel/UCLX_NchE8lisC4NL2GciIWA        EPISODE CREDITS Intro music provided by Tony Palacios - https://www.instagram.com/tonytonedog/       Outro music provided by Jeff Scheetz - https://jeffscheetz.com/